Scientists from Yale School of Medicine are calling on willing participants for one of two clinical trials for pharmaceutical treatments against Alzheimer's disease, which until this day, scientists have yet to find a cure for. The only drugs available on the market today are indicated for symptomatic treatment. Unfortunately, this form of dementia is a common cause of mortality among the aging population.
One of the trials will test T-817MA by Toyama Chemical Co. Ltd. as part of the NOBLE study on patients diagnosed with a mild to moderate state of the disease. This study takes place in two Connecticut sites, with Geriatric and Adult Psychiatry in Hamden being the second.
The director of the Alzheimer's Research Disease unit at Yale, Dr. Christopher van Dyck, said that the NOBLE study is working towards finding a drug that can actually slow Alzheimer's progression in terms of neuronal damage. This year-long Phase II study is already underway, but there is still a need for a total of 450 participants across more than 40 study sites, 67% of whom have a fair chance at receiving the drug over a placebo.
The second trial is dubbe